Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States
•As COVID-19 vaccines become available, it is important to understand rates of vaccine acceptability in adults with multiple sclerosis (MS).•Two-thirds of the participants reported a willingness to obtain a COVID-19 vaccine, with education level, perceived risk for COVID-19, and trust in COVID-19 in...
Saved in:
| Published in: | Multiple sclerosis and related disorders Vol. 49; p. 102788 |
|---|---|
| Main Authors: | , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Netherlands
Elsevier B.V
01.04.2021
|
| Subjects: | |
| ISSN: | 2211-0348, 2211-0356, 2211-0356 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | •As COVID-19 vaccines become available, it is important to understand rates of vaccine acceptability in adults with multiple sclerosis (MS).•Two-thirds of the participants reported a willingness to obtain a COVID-19 vaccine, with education level, perceived risk for COVID-19, and trust in COVID-19 information sources positively associated with vaccine acceptability.•These findings have important implications for guiding vaccine uptake among vaccine eligible people with MS during the COVID-19 pandemic.
Background: As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS in the United States obtained early in the COVID-19 pandemic, the current study aimed to: (1) assess willingness to get a COVID-19 vaccine when available; (2) determine demographic, MS, and psychosocial correlates of vaccine willingness; and (3) measure where people with MS get their COVID-19 information and their perceived trustworthiness of such sources, which may influence COVID-19 vaccine willingness.
Methods: Adults with MS (N = 486) living in the United States completed a cross-sectional online survey (between 10 April 2020 and 06 May 2020) about their willingness to receive a COVID-19 vaccination once available. Participants also completed measures to describe the sample and to assess factors potentially related to vaccine willingness, including demographics, MS-specific variables, psychological measures, COVID-19 information sources, and perceived trustworthiness of their information sources.
Results: Approximately two-thirds of the participants (66.0%) reported a willingness to obtain a future COVID-19 vaccine, whereas 15.4%of the sample was unwilling. Greater willingness to receive the vaccine was associated with having a higher level of education and holding a higher perception of one's risk of catching COVID-19. Participants reported accessing COVID-19 information from many different sources. Approximately a third (31.6%) of the sample reported getting their information from healthcare providers. Healthcare providers and the National MS Society had the highest perceived trustworthiness for COVID-19 information. The perceived trustworthiness of information sources was highly associated with vaccine willingness.
Conclusion: Early in the pandemic, willingness to get a COVID-19 vaccine was not universal in this large sample or people living with MS. Vaccine willingness was associated with a few variables including education level, perceived risk for COVID-19 infection, and trust in COVID-19 information sources. These results have important implications for guiding healthcare providers and the MS community as COVID-19 vaccines become widely available. |
|---|---|
| AbstractList | As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS in the United States obtained early in the COVID-19 pandemic, the current study aimed to: (1) assess willingness to get a COVID-19 vaccine when available; (2) determine demographic, MS, and psychosocial correlates of vaccine willingness; and (3) measure where people with MS get their COVID-19 information and their perceived trustworthiness of such sources, which may influence COVID-19 vaccine willingness.BACKGROUNDAs vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS in the United States obtained early in the COVID-19 pandemic, the current study aimed to: (1) assess willingness to get a COVID-19 vaccine when available; (2) determine demographic, MS, and psychosocial correlates of vaccine willingness; and (3) measure where people with MS get their COVID-19 information and their perceived trustworthiness of such sources, which may influence COVID-19 vaccine willingness.Adults with MS (N = 486) living in the United States completed a cross-sectional online survey (between 10 April 2020 and 06 May 2020) about their willingness to receive a COVID-19 vaccination once available. Participants also completed measures to describe the sample and to assess factors potentially related to vaccine willingness, including demographics, MS-specific variables, psychological measures, COVID-19 information sources, and perceived trustworthiness of their information sources.METHODSAdults with MS (N = 486) living in the United States completed a cross-sectional online survey (between 10 April 2020 and 06 May 2020) about their willingness to receive a COVID-19 vaccination once available. Participants also completed measures to describe the sample and to assess factors potentially related to vaccine willingness, including demographics, MS-specific variables, psychological measures, COVID-19 information sources, and perceived trustworthiness of their information sources.Approximately two-thirds of the participants (66.0%) reported a willingness to obtain a future COVID-19 vaccine, whereas 15.4%of the sample was unwilling. Greater willingness to receive the vaccine was associated with having a higher level of education and holding a higher perception of one's risk of catching COVID-19. Participants reported accessing COVID-19 information from many different sources. Approximately a third (31.6%) of the sample reported getting their information from healthcare providers. Healthcare providers and the National MS Society had the highest perceived trustworthiness for COVID-19 information. The perceived trustworthiness of information sources was highly associated with vaccine willingness.RESULTSApproximately two-thirds of the participants (66.0%) reported a willingness to obtain a future COVID-19 vaccine, whereas 15.4%of the sample was unwilling. Greater willingness to receive the vaccine was associated with having a higher level of education and holding a higher perception of one's risk of catching COVID-19. Participants reported accessing COVID-19 information from many different sources. Approximately a third (31.6%) of the sample reported getting their information from healthcare providers. Healthcare providers and the National MS Society had the highest perceived trustworthiness for COVID-19 information. The perceived trustworthiness of information sources was highly associated with vaccine willingness.Early in the pandemic, willingness to get a COVID-19 vaccine was not universal in this large sample or people living with MS. Vaccine willingness was associated with a few variables including education level, perceived risk for COVID-19 infection, and trust in COVID-19 information sources. These results have important implications for guiding healthcare providers and the MS community as COVID-19 vaccines become widely available.CONCLUSIONEarly in the pandemic, willingness to get a COVID-19 vaccine was not universal in this large sample or people living with MS. Vaccine willingness was associated with a few variables including education level, perceived risk for COVID-19 infection, and trust in COVID-19 information sources. These results have important implications for guiding healthcare providers and the MS community as COVID-19 vaccines become widely available. •As COVID-19 vaccines become available, it is important to understand rates of vaccine acceptability in adults with multiple sclerosis (MS).•Two-thirds of the participants reported a willingness to obtain a COVID-19 vaccine, with education level, perceived risk for COVID-19, and trust in COVID-19 information sources positively associated with vaccine acceptability.•These findings have important implications for guiding vaccine uptake among vaccine eligible people with MS during the COVID-19 pandemic. Background: As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS in the United States obtained early in the COVID-19 pandemic, the current study aimed to: (1) assess willingness to get a COVID-19 vaccine when available; (2) determine demographic, MS, and psychosocial correlates of vaccine willingness; and (3) measure where people with MS get their COVID-19 information and their perceived trustworthiness of such sources, which may influence COVID-19 vaccine willingness. Methods: Adults with MS (N = 486) living in the United States completed a cross-sectional online survey (between 10 April 2020 and 06 May 2020) about their willingness to receive a COVID-19 vaccination once available. Participants also completed measures to describe the sample and to assess factors potentially related to vaccine willingness, including demographics, MS-specific variables, psychological measures, COVID-19 information sources, and perceived trustworthiness of their information sources. Results: Approximately two-thirds of the participants (66.0%) reported a willingness to obtain a future COVID-19 vaccine, whereas 15.4%of the sample was unwilling. Greater willingness to receive the vaccine was associated with having a higher level of education and holding a higher perception of one's risk of catching COVID-19. Participants reported accessing COVID-19 information from many different sources. Approximately a third (31.6%) of the sample reported getting their information from healthcare providers. Healthcare providers and the National MS Society had the highest perceived trustworthiness for COVID-19 information. The perceived trustworthiness of information sources was highly associated with vaccine willingness. Conclusion: Early in the pandemic, willingness to get a COVID-19 vaccine was not universal in this large sample or people living with MS. Vaccine willingness was associated with a few variables including education level, perceived risk for COVID-19 infection, and trust in COVID-19 information sources. These results have important implications for guiding healthcare providers and the MS community as COVID-19 vaccines become widely available. Background: As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS in the United States obtained early in the COVID-19 pandemic, the current study aimed to: (1) assess willingness to get a COVID-19 vaccine when available; (2) determine demographic, MS, and psychosocial correlates of vaccine willingness; and (3) measure where people with MS get their COVID-19 information and their perceived trustworthiness of such sources, which may influence COVID-19 vaccine willingness. Methods: Adults with MS (N = 486) living in the United States completed a cross-sectional online survey (between 10 April 2020 and 06 May 2020) about their willingness to receive a COVID-19 vaccination once available. Participants also completed measures to describe the sample and to assess factors potentially related to vaccine willingness, including demographics, MS-specific variables, psychological measures, COVID-19 information sources, and perceived trustworthiness of their information sources. Results: Approximately two-thirds of the participants (66.0%) reported a willingness to obtain a future COVID-19 vaccine, whereas 15.4%of the sample was unwilling. Greater willingness to receive the vaccine was associated with having a higher level of education and holding a higher perception of one's risk of catching COVID-19. Participants reported accessing COVID-19 information from many different sources. Approximately a third (31.6%) of the sample reported getting their information from healthcare providers. Healthcare providers and the National MS Society had the highest perceived trustworthiness for COVID-19 information. The perceived trustworthiness of information sources was highly associated with vaccine willingness. Conclusion: Early in the pandemic, willingness to get a COVID-19 vaccine was not universal in this large sample or people living with MS. Vaccine willingness was associated with a few variables including education level, perceived risk for COVID-19 infection, and trust in COVID-19 information sources. These results have important implications for guiding healthcare providers and the MS community as COVID-19 vaccines become widely available. Highlights•As COVID-19 vaccines become available, it is important to understand rates of vaccine acceptability in adults with multiple sclerosis (MS). •Two-thirds of the participants reported a willingness to obtain a COVID-19 vaccine, with education level, perceived risk for COVID-19, and trust in COVID-19 information sources positively associated with vaccine acceptability. •These findings have important implications for guiding vaccine uptake among vaccine eligible people with MS during the COVID-19 pandemic. As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis (MS), given that vaccination will be a key strategy for preventing SARS-CoV-2 infections. Using a national sample of adults with MS in the United States obtained early in the COVID-19 pandemic, the current study aimed to: (1) assess willingness to get a COVID-19 vaccine when available; (2) determine demographic, MS, and psychosocial correlates of vaccine willingness; and (3) measure where people with MS get their COVID-19 information and their perceived trustworthiness of such sources, which may influence COVID-19 vaccine willingness. Adults with MS (N = 486) living in the United States completed a cross-sectional online survey (between 10 April 2020 and 06 May 2020) about their willingness to receive a COVID-19 vaccination once available. Participants also completed measures to describe the sample and to assess factors potentially related to vaccine willingness, including demographics, MS-specific variables, psychological measures, COVID-19 information sources, and perceived trustworthiness of their information sources. Approximately two-thirds of the participants (66.0%) reported a willingness to obtain a future COVID-19 vaccine, whereas 15.4%of the sample was unwilling. Greater willingness to receive the vaccine was associated with having a higher level of education and holding a higher perception of one's risk of catching COVID-19. Participants reported accessing COVID-19 information from many different sources. Approximately a third (31.6%) of the sample reported getting their information from healthcare providers. Healthcare providers and the National MS Society had the highest perceived trustworthiness for COVID-19 information. The perceived trustworthiness of information sources was highly associated with vaccine willingness. Early in the pandemic, willingness to get a COVID-19 vaccine was not universal in this large sample or people living with MS. Vaccine willingness was associated with a few variables including education level, perceived risk for COVID-19 infection, and trust in COVID-19 information sources. These results have important implications for guiding healthcare providers and the MS community as COVID-19 vaccines become widely available. |
| ArticleNumber | 102788 |
| Author | Herring, Tracy E. Ehde, Dawn M. Roberts, Michelle K. Alschuler, Kevin N. |
| Author_xml | – sequence: 1 givenname: Dawn M. orcidid: 0000-0002-9555-2347 surname: Ehde fullname: Ehde, Dawn M. email: ehde@uw.edu organization: Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA – sequence: 2 givenname: Michelle K. orcidid: 0000-0003-4908-704X surname: Roberts fullname: Roberts, Michelle K. organization: Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA – sequence: 3 givenname: Tracy E. surname: Herring fullname: Herring, Tracy E. organization: Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA – sequence: 4 givenname: Kevin N. surname: Alschuler fullname: Alschuler, Kevin N. organization: Department of Rehabilitation Medicine, University of Washington, Seattle, WA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33508570$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUl1vEzEQtFAR_aC_AAndIy8XvPb54hOiEgoFKlXqQyk8Wo69aRwcO5x9Qf33-Jq2gkpQv3i1npm1duaQ7IUYkJBXQCdAoX27mqyT7u2EUQalw6ZSPiMHjAHUlIt276Fu5D45TmlFy2kFNC28IPucCyrFlB4Q_d1578J1wJSqHKs4z9qFanbx7exjDV211ca4oLOLoSp9bQefU_XL5WW1LqXbeKyS8djH5NKIyEusroLLaKvLrDOml-T5QvuEx3f3Ebn6dPp19qU-v_h8NvtwXhvRtrnmiFQy6Bg1IHVj5xbQiIXApiu_ptw0ums7S22jETQ1DdccOxAwR2OBM35ETna6m2G-Rmsw5F57tendWvc3Kmqn_n4Jbqmu41ZNJRNSQBF4cyfQx58DpqzWLhn0XgeMQ1KskVwCtF1XoK__nPUw5H6vBdDtAKYsJvW4UMbl2y2W0c4roGq0Ua3UrY1qtFHtbCxc_oh7L_9_1vsdC8uOtw57lYzDYNC6Hk1WNron-CeP-Kbkwhntf-ANplUc-lDsU6ASU1RdjvEa08WgBEs00yLw7t8CT47_DTQ_4J0 |
| CitedBy_id | crossref_primary_10_1016_j_msard_2021_103163 crossref_primary_10_1212_NXI_0000000000001104 crossref_primary_10_1007_s12325_021_01761_3 crossref_primary_10_1016_j_heliyon_2023_e18079 crossref_primary_10_1016_j_msard_2021_103045 crossref_primary_10_1177_23333928221106269 crossref_primary_10_1007_s00393_022_01213_5 crossref_primary_10_1016_j_msard_2022_103723 crossref_primary_10_1080_13504851_2022_2087857 crossref_primary_10_1016_j_pediatrneurol_2023_02_017 crossref_primary_10_3390_ijerph19063366 crossref_primary_10_1016_j_dhjo_2021_101223 crossref_primary_10_1212_CPJ_0000000000001164 crossref_primary_10_1192_bjo_2021_979 crossref_primary_10_3390_vaccines9080900 crossref_primary_10_3390_vaccines10010135 crossref_primary_10_3390_vaccines9070745 crossref_primary_10_25122_jml_2022_0086 crossref_primary_10_1016_j_msard_2022_104172 crossref_primary_10_3389_fpubh_2021_770985 crossref_primary_10_3390_ijerph19116816 crossref_primary_10_3390_vaccines9030292 crossref_primary_10_1016_j_jiph_2021_08_002 crossref_primary_10_1016_j_msard_2021_103175 crossref_primary_10_1177_13524585211030647 crossref_primary_10_3390_brainsci11070890 crossref_primary_10_3390_vaccines9111243 crossref_primary_10_1111_ene_15028 crossref_primary_10_3390_vaccines10071097 crossref_primary_10_3390_vaccines10091488 crossref_primary_10_1007_s40609_023_00268_9 crossref_primary_10_1007_s10072_022_06051_6 crossref_primary_10_1097_WCO_0000000000001066 crossref_primary_10_3390_ijerph18178892 crossref_primary_10_3389_fneur_2022_847873 crossref_primary_10_1038_s41598_022_18912_3 crossref_primary_10_3390_vaccines13050451 crossref_primary_10_3390_vaccines9080873 crossref_primary_10_1016_j_jadohealth_2022_01_003 crossref_primary_10_1177_20552173211017159 crossref_primary_10_1177_20552173221085242 crossref_primary_10_3389_fneur_2021_757038 crossref_primary_10_3390_jcm12175460 crossref_primary_10_1186_s41983_022_00573_8 crossref_primary_10_3390_jcm14113689 crossref_primary_10_4103_1673_5374_346539 crossref_primary_10_1016_j_msard_2021_103189 crossref_primary_10_7759_cureus_54852 crossref_primary_10_3390_vaccines9111276 crossref_primary_10_1088_2752_5309_ac8ac2 crossref_primary_10_1177_17562864211058298 crossref_primary_10_1186_s12888_022_03830_5 crossref_primary_10_1016_j_clineuro_2022_107374 crossref_primary_10_3389_fmed_2021_783982 crossref_primary_10_2147_RMHP_S311074 crossref_primary_10_5812_ans_137636 crossref_primary_10_1007_s00415_021_10780_7 crossref_primary_10_1016_j_msard_2024_106253 crossref_primary_10_3390_vaccines11020239 crossref_primary_10_3390_vaccines12040414 crossref_primary_10_1016_j_msard_2021_103113 crossref_primary_10_1016_j_msard_2021_103236 crossref_primary_10_1016_j_msard_2022_103933 crossref_primary_10_7759_cureus_73161 crossref_primary_10_1177_2333794X211048738 crossref_primary_10_1002_pmrj_12668 crossref_primary_10_3390_vaccines9070773 crossref_primary_10_1007_s13311_021_01165_9 crossref_primary_10_17116_jnevro202312307229 crossref_primary_10_1007_s40615_023_01882_1 crossref_primary_10_3390_ijerph19074205 crossref_primary_10_1002_hsr2_70119 crossref_primary_10_3389_fpubh_2022_998234 |
| Cites_doi | 10.1016/j.eclinm.2020.100495 10.1089/bsp.2012.0048 10.1212/WNL.0000000000009507 10.1016/j.jbi.2008.08.010 10.1007/s10900-020-00958-x 10.7326/M20-3569 10.1186/1471-2377-13-37 10.7224/1537-2073.2014-044 10.1001/jamanetworkopen.2020.25594 10.1111/bjhp.12468 10.1016/j.vaccine.2020.08.043 10.1016/j.vaccine.2017.12.016 10.1007/s10654-020-00671-y 10.1016/j.jclinepi.2010.04.011 10.2147/RMHP.S4810 10.3389/fpsyg.2020.575950 10.1016/j.vaccine.2015.04.040 |
| ContentType | Journal Article |
| Copyright | 2021 Elsevier B.V. Elsevier B.V. Copyright © 2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V. |
| Copyright_xml | – notice: 2021 Elsevier B.V. – notice: Elsevier B.V. – notice: Copyright © 2021 Elsevier B.V. All rights reserved. – notice: 2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.msard.2021.102788 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2211-0356 |
| EndPage | 102788 |
| ExternalDocumentID | PMC7825851 33508570 10_1016_j_msard_2021_102788 S2211034821000547 1_s2_0_S2211034821000547 |
| Genre | Journal Article |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1P~ 1~. 1~5 4.4 457 4G. 53G 5VS 7-5 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABGSF ABJNI ABMAC ABMZM ABTEW ABUDA ABWVN ABXDB ACDAQ ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV EBS EFJIC EFKBS EFLBG EJD FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MO0 MOBAO O-L O9- OAUVE OP~ P-8 P-9 PC. Q38 ROL SDF SEL SPCBC SSH SSN SSU SSZ T5K Z5R ~G- ~HD AACTN AFKWA AJOXV AMFUW RIG AADPK AAIAV ABLVK ABYKQ AJBFU DOVZS LCYCR AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c566t-3ee0821920c18a4dbd1ec5f5e4951403c4a969d0d4ae1a0c43a3e9151becd1323 |
| ISICitedReferencesCount | 80 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000641392000011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2211-0348 2211-0356 |
| IngestDate | Tue Sep 30 16:57:49 EDT 2025 Sun Nov 09 10:51:44 EST 2025 Mon Jul 21 05:51:02 EDT 2025 Tue Nov 18 20:36:46 EST 2025 Wed Nov 05 20:50:45 EST 2025 Fri Feb 23 02:44:36 EST 2024 Tue Feb 25 20:07:13 EST 2025 Tue Oct 14 19:33:39 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Keywords | COVID-19 Multiple sclerosis Vaccine Coronavirus |
| Language | English |
| License | Copyright © 2021 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c566t-3ee0821920c18a4dbd1ec5f5e4951403c4a969d0d4ae1a0c43a3e9151becd1323 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-4908-704X 0000-0002-9555-2347 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7825851 |
| PMID | 33508570 |
| PQID | 2483811699 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7825851 proquest_miscellaneous_2483811699 pubmed_primary_33508570 crossref_citationtrail_10_1016_j_msard_2021_102788 crossref_primary_10_1016_j_msard_2021_102788 elsevier_sciencedirect_doi_10_1016_j_msard_2021_102788 elsevier_clinicalkeyesjournals_1_s2_0_S2211034821000547 elsevier_clinicalkey_doi_10_1016_j_msard_2021_102788 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-04-01 |
| PublicationDateYYYYMMDD | 2021-04-01 |
| PublicationDate_xml | – month: 04 year: 2021 text: 2021-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Multiple sclerosis and related disorders |
| PublicationTitleAlternate | Mult Scler Relat Disord |
| PublicationYear | 2021 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Quinn, Parmer, Freimuth, Hilyard, Musa, Kim (bib0005) 2013; 11 Fisher, Bloomstone, Walder, Crawford, Fouayzi, Mazor (bib0004) 2020 Malik, McFadden, Elharake, Omer (bib0003) 2020; 26 Taylor, Raphael, Barr, Agho, Stevens, Jorm (bib0009) 2009; 2 Taylor, Landry, Paluszek, Groenewoud, Rachor, Asmundson (bib0017) 2020; 11 Alschuler, Beier (bib0012) 2015; 17 Society (bib0019) 2020 Lu, Srivastav, Amaya (bib0018) 2018; 36 Brownlee, Bourdette, Broadley, Killestein, Ciccarelli (bib0006) 2020; 94 Khubchandani, Sharma, Price, Wiblishauser, Sharma, Webb (bib0014) 2021 Jarrett, Wilson, O'Leary, Eckersberger, Larson, SWGoV (bib0020) 2015; 33 Alschuler, Roberts, Herring, Ehde (bib0007) 2020; 47 Center (bib0013) December 2020 Learmonth, Motl, Sandroff, Pula, Cadavid (bib0010) 2013; 13 Williams, Gallant, Rasmussen (bib0015) 2020; 25 Cella, Riley, Stone (bib0011) 2010; 63 Kreps, Prasad, Brownstein (bib0016) 2020; 3 Dror, Eisenbach, Taiber (bib0002) 2020; 35 Reiter, Pennell, Katz (bib0001) 2020; 38 Harris, Taylor, Thielke, Payne, Gonzalez, Conde (bib0008) 2009; 42 Jarrett (10.1016/j.msard.2021.102788_bib0020) 2015; 33 Malik (10.1016/j.msard.2021.102788_bib0003) 2020; 26 Dror (10.1016/j.msard.2021.102788_bib0002) 2020; 35 Center (10.1016/j.msard.2021.102788_bib0013) 2020 Williams (10.1016/j.msard.2021.102788_bib0015) 2020; 25 Learmonth (10.1016/j.msard.2021.102788_bib0010) 2013; 13 Kreps (10.1016/j.msard.2021.102788_bib0016) 2020; 3 Fisher (10.1016/j.msard.2021.102788_bib0004) 2020 Taylor (10.1016/j.msard.2021.102788_bib0009) 2009; 2 Alschuler (10.1016/j.msard.2021.102788_bib0012) 2015; 17 Society (10.1016/j.msard.2021.102788_bib0019) 2020 Taylor (10.1016/j.msard.2021.102788_bib0017) 2020; 11 Brownlee (10.1016/j.msard.2021.102788_bib0006) 2020; 94 Cella (10.1016/j.msard.2021.102788_bib0011) 2010; 63 Quinn (10.1016/j.msard.2021.102788_bib0005) 2013; 11 Khubchandani (10.1016/j.msard.2021.102788_bib0014) 2021 Reiter (10.1016/j.msard.2021.102788_bib0001) 2020; 38 Harris (10.1016/j.msard.2021.102788_bib0008) 2009; 42 Alschuler (10.1016/j.msard.2021.102788_bib0007) 2020; 47 Lu (10.1016/j.msard.2021.102788_bib0018) 2018; 36 |
| References_xml | – volume: 26 year: 2020 ident: bib0003 article-title: Determinants of COVID-19 vaccine acceptance in the US publication-title: EClinicalMedicine – volume: 36 start-page: 890 year: 2018 end-page: 898 ident: bib0018 article-title: Association of provider recommendation and offer and influenza vaccination among adults aged >/=18years - United States publication-title: Vaccine – year: 2020 ident: bib0019 article-title: COVID-19 Vaccine Guidance for People Living with MS – year: 2020 ident: bib0004 article-title: Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults publication-title: Ann Intern Med – volume: 2 start-page: 9 year: 2009 end-page: 20 ident: bib0009 article-title: Public health measures during an anticipated influenza pandemic: Factors influencing willingness to comply publication-title: Risk Manag Healthc Policy – volume: 11 start-page: 96 year: 2013 end-page: 106 ident: bib0005 article-title: Exploring communication, trust in government, and vaccination intention later in the 2009 H1N1 pandemic: results of a national survey publication-title: Biosecur Bioterror – volume: 47 year: 2020 ident: bib0007 article-title: Distress and risk perception in people living with multiple sclerosis during the early phase of the COVID-19 pandemic publication-title: Mult Scler Relat Disord – volume: 38 start-page: 6500 year: 2020 end-page: 6507 ident: bib0001 article-title: Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? publication-title: Vaccine – volume: 63 start-page: 1179 year: 2010 end-page: 1194 ident: bib0011 article-title: The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks publication-title: J Clin Epidemiol – volume: 17 start-page: 153 year: 2015 end-page: 158 ident: bib0012 article-title: Intolerance of Uncertainty: Shaping an Agenda for Research on Coping with Multiple Sclerosis publication-title: Int J MS Care – volume: 42 start-page: 377 year: 2009 end-page: 381 ident: bib0008 article-title: Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support publication-title: Journal of biomedical informatics – year: December 2020 ident: bib0013 article-title: Intent to get a COVID-19 vaccine rises to 60% as confidence in research and development process increases – volume: 25 start-page: 1039 year: 2020 end-page: 1054 ident: bib0015 article-title: Towards intervention development to increase the uptake of COVID-19 vaccination among those at high risk: Outlining evidence-based and theoretically informed future intervention content publication-title: Br J Health Psychol – volume: 33 start-page: 4180 year: 2015 end-page: 4190 ident: bib0020 article-title: Strategies for addressing vaccine hesitancy - A systematic review publication-title: Vaccine – volume: 11 year: 2020 ident: bib0017 article-title: A Proactive Approach for Managing COVID-19: The Importance of Understanding the Motivational Roots of Vaccination Hesitancy for SARS-CoV2 publication-title: Front Psychol – year: 2021 ident: bib0014 article-title: COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment publication-title: J Community Health – volume: 94 start-page: 949 year: 2020 end-page: 952 ident: bib0006 article-title: Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic publication-title: Neurology – volume: 35 start-page: 775 year: 2020 end-page: 779 ident: bib0002 article-title: Vaccine hesitancy: the next challenge in the fight against COVID-19 publication-title: Eur J Epidemiol – volume: 3 year: 2020 ident: bib0016 article-title: Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination publication-title: JAMA Netw Open – volume: 13 start-page: 37 year: 2013 ident: bib0010 article-title: Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis publication-title: BMC neurology – volume: 26 year: 2020 ident: 10.1016/j.msard.2021.102788_bib0003 article-title: Determinants of COVID-19 vaccine acceptance in the US publication-title: EClinicalMedicine doi: 10.1016/j.eclinm.2020.100495 – volume: 11 start-page: 96 issue: 2 year: 2013 ident: 10.1016/j.msard.2021.102788_bib0005 article-title: Exploring communication, trust in government, and vaccination intention later in the 2009 H1N1 pandemic: results of a national survey publication-title: Biosecur Bioterror doi: 10.1089/bsp.2012.0048 – volume: 94 start-page: 949 issue: 22 year: 2020 ident: 10.1016/j.msard.2021.102788_bib0006 article-title: Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic publication-title: Neurology doi: 10.1212/WNL.0000000000009507 – volume: 42 start-page: 377 issue: 2 year: 2009 ident: 10.1016/j.msard.2021.102788_bib0008 article-title: Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support publication-title: Journal of biomedical informatics doi: 10.1016/j.jbi.2008.08.010 – year: 2020 ident: 10.1016/j.msard.2021.102788_bib0019 – year: 2021 ident: 10.1016/j.msard.2021.102788_bib0014 article-title: COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment publication-title: J Community Health doi: 10.1007/s10900-020-00958-x – year: 2020 ident: 10.1016/j.msard.2021.102788_bib0004 article-title: Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults publication-title: Ann Intern Med doi: 10.7326/M20-3569 – volume: 13 start-page: 37 year: 2013 ident: 10.1016/j.msard.2021.102788_bib0010 article-title: Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis publication-title: BMC neurology doi: 10.1186/1471-2377-13-37 – volume: 47 year: 2020 ident: 10.1016/j.msard.2021.102788_bib0007 article-title: Distress and risk perception in people living with multiple sclerosis during the early phase of the COVID-19 pandemic publication-title: Mult Scler Relat Disord – volume: 17 start-page: 153 issue: 4 year: 2015 ident: 10.1016/j.msard.2021.102788_bib0012 article-title: Intolerance of Uncertainty: Shaping an Agenda for Research on Coping with Multiple Sclerosis publication-title: Int J MS Care doi: 10.7224/1537-2073.2014-044 – volume: 3 issue: 10 year: 2020 ident: 10.1016/j.msard.2021.102788_bib0016 article-title: Factors Associated With US Adults' Likelihood of Accepting COVID-19 Vaccination publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2020.25594 – volume: 25 start-page: 1039 issue: 4 year: 2020 ident: 10.1016/j.msard.2021.102788_bib0015 article-title: Towards intervention development to increase the uptake of COVID-19 vaccination among those at high risk: Outlining evidence-based and theoretically informed future intervention content publication-title: Br J Health Psychol doi: 10.1111/bjhp.12468 – year: 2020 ident: 10.1016/j.msard.2021.102788_bib0013 – volume: 38 start-page: 6500 issue: 42 year: 2020 ident: 10.1016/j.msard.2021.102788_bib0001 article-title: Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? publication-title: Vaccine doi: 10.1016/j.vaccine.2020.08.043 – volume: 36 start-page: 890 issue: 6 year: 2018 ident: 10.1016/j.msard.2021.102788_bib0018 article-title: Association of provider recommendation and offer and influenza vaccination among adults aged >/=18years - United States publication-title: Vaccine doi: 10.1016/j.vaccine.2017.12.016 – volume: 35 start-page: 775 issue: 8 year: 2020 ident: 10.1016/j.msard.2021.102788_bib0002 article-title: Vaccine hesitancy: the next challenge in the fight against COVID-19 publication-title: Eur J Epidemiol doi: 10.1007/s10654-020-00671-y – volume: 63 start-page: 1179 issue: 11 year: 2010 ident: 10.1016/j.msard.2021.102788_bib0011 article-title: The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2010.04.011 – volume: 2 start-page: 9 year: 2009 ident: 10.1016/j.msard.2021.102788_bib0009 article-title: Public health measures during an anticipated influenza pandemic: Factors influencing willingness to comply publication-title: Risk Manag Healthc Policy doi: 10.2147/RMHP.S4810 – volume: 11 year: 2020 ident: 10.1016/j.msard.2021.102788_bib0017 article-title: A Proactive Approach for Managing COVID-19: The Importance of Understanding the Motivational Roots of Vaccination Hesitancy for SARS-CoV2 publication-title: Front Psychol doi: 10.3389/fpsyg.2020.575950 – volume: 33 start-page: 4180 issue: 34 year: 2015 ident: 10.1016/j.msard.2021.102788_bib0020 article-title: Strategies for addressing vaccine hesitancy - A systematic review publication-title: Vaccine doi: 10.1016/j.vaccine.2015.04.040 |
| SSID | ssj0000651461 |
| Score | 2.485359 |
| Snippet | •As COVID-19 vaccines become available, it is important to understand rates of vaccine acceptability in adults with multiple sclerosis (MS).•Two-thirds of the... Highlights•As COVID-19 vaccines become available, it is important to understand rates of vaccine acceptability in adults with multiple sclerosis (MS).... As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple sclerosis... Background: As vaccines for the coronavirus become available, it will be important to know the rate of COVID-19 vaccine acceptability in adults with multiple... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 102788 |
| SubjectTerms | Adolescent Adult Aged Aged, 80 and over Coronavirus COVID-19 COVID-19 - prevention & control COVID-19 Vaccines - administration & dosage Cross-Sectional Studies Female Humans Male Middle Aged Multiple sclerosis Multiple Sclerosis - epidemiology Neurology Pandemics United States - epidemiology Vaccination - psychology Vaccination Refusal - psychology Vaccine Young Adult |
| Title | Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2211034821000547 https://www.clinicalkey.es/playcontent/1-s2.0-S2211034821000547 https://dx.doi.org/10.1016/j.msard.2021.102788 https://www.ncbi.nlm.nih.gov/pubmed/33508570 https://www.proquest.com/docview/2483811699 https://pubmed.ncbi.nlm.nih.gov/PMC7825851 |
| Volume | 49 |
| WOSCitedRecordID | wos000641392000011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect database customDbUrl: eissn: 2211-0356 dateEnd: 20210531 omitProxy: false ssIdentifier: ssj0000651461 issn: 2211-0348 databaseCode: AIEXJ dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6DaG9ID5H-ZiMhHgZqZI4aZLHauu0wdYh0aG-Wa7jsk5dWpa2jL-Ff5a72E5aWsZ44CWqXLtOc7-c787n3xHylrEgFQJpQ0UqnQDJhmIplaOaAzdI4z5SwhXFJqJOJ-71kk-12k97FmY-irIsvrlJJv9V1NAGwsajs_8g7vJHoQE-g9DhCmKH650EX0RQsq-FCgPDctxH539v_-zL8YHjJXtzIeVQhwAx1lHwb5gjbmVyYQ4_CavnMLdZkEuW6aI9e7o6pEhYxxQ7GJAabs_KcL_QNL8H4ntWBWJ1endu0_hxL6EKvx4hd6TWSLCwyh_V2YnWCFzzmTnK-BFW-MxsLJkohu8tJL8Uys73MVTLQkOLvabNaGtNcGrUrYf7pvHalUAHJS4bVzm8aQ2cslH1Xubd7pzxw_OTE95t97rvJt8cLEmGW_emPssG2fKjMAGVudU6bvc-lCE8sN6wKjqWL7R3anmtigzClan_ZPus-ja_p-gu2Dzdh-SBcVZoS4PsEamp7DG5f2rSMZ4QsYA1Oh1TjTVqsUYXsEahXWONItaoxRotgYM9AGtUY41qrD0l54ft7v6RY2p2OBIcg6nDlAKjEtwGV3qxCNJ-6ikZDkIFjjhSQ8pAJM0kddNAKE-4MmCCqQTMTtAlqcd89oxsZuNMPSc0DGUagbmrokEcKNmE5RB8WxWwJnIpK1Ynvn2aXBpCe6yrMuI2c_GSFyLgKAKuRVAn78tBE83ncnv3wIqJ26PKsLhyQNntw6J1w1Ru9ETOPZ773OWfETkuEkx5hfcU1UmzHGlsYG3b_n3KNxZFHFYI3PYTmRrPcu4HMZjlHjy1OtnRqCr_OmNhUeICbngJb2UHZJ9f_iYbXhQs9OBaYErBizvM-5JsV-_8K7I5vZ6p1-SenE-H-fUu2Yh68a55uX4B5zX7lw |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Willingness+to+obtain+COVID-19+vaccination+in+adults+with+multiple+sclerosis+in+the+United+States&rft.jtitle=Multiple+sclerosis+and+related+disorders&rft.au=Ehde%2C+Dawn+M&rft.au=Roberts%2C+Michelle+K&rft.au=Herring%2C+Tracy+E&rft.au=Alschuler%2C+Kevin+N&rft.date=2021-04-01&rft.issn=2211-0356&rft.eissn=2211-0356&rft.volume=49&rft.spage=102788&rft_id=info:doi/10.1016%2Fj.msard.2021.102788&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2211-0348&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2211-0348&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2211-0348&client=summon |